Skip to main content

Table 1 Anthropometric and laboratory characteristics of healthy subjects, NAFLD, T2DM and NAFLD + T2DM

From: The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study

Characteristics

Healthy subjects (N = 21)

NAFLD (N = 22)

T2DM (N = 22)

NAFLD + T2DM (N = 22)

Total difference p value

Age, years

51 (48–60)

51 (48–55)

57.5 (47–60)

52 (45–57)

ns

WC, cm

93.29 ± 2.14

104.95 ± 1.49

100.43 ± 2.38

109.61 ± 2.23

<0.001

Hip, cm

99.29 ± 1.23

105.32 ± 1.2

100.77 ± 1.51

107.73 ± 73

<0.001

WHR, –

0.94 ± 0.01

1.00 ± 0.01

0.99 ± 0.02

1.02 ± 0.02

<0.001

BMI, kg/m2

24.76 ± 0.80

29.18 ± 0.50

27.28 ± 0.91

30.61 ± 0.84

<0.001

FBG, mg/dL

89.46 (84.10–96.56)

95.82 (90.10–100.70)

129.95 (123.20–175.20)

155 (127.00–187.95)

<0.001

Insulin, µU/mL

3.5 (2.7–4.9)

9.6 (9.2–12)

6.35 (2.2–8.9)

8.5 (6.3–10.6)

<0.001

HOMA-IR, –

0.75 (0.56–1.23)

2.32 (1.89–2.89)

2.46 (0.91–3.17)

2.64 (1.99–5.51)

<0.001

TG, mg/dL

114.65 (89.95–154)

143.95 (109.1–164.8)

138.7 (105.3–163.7)

165.6 (113.75–241.05)

ns

TC, mg/dL

190.01 ± 6.69

201.45 ± 7.64

195.84 ± 9.67

191.42 ± 16.17

ns

HDL-C, mg/dL

54.39 ± 2.78

48.61 ± 2.16

54.22 ± 2.88

49.79 ± 3.98

ns

LDL-C, mg/dL

111.65 ± 6.41

117.73 ± 7.75

113.76 ± 7.85

109.22 ± 10.53

ns

LDL-C/HDL-C, –

2.12 ± 0.14

2.42 ± 0.15

2.13 ± 0.13

2.04 ± 0.19

ns

TC/HDL-C, –

3.65 ± 0.16

4.24 ± 0.17

3.69 ± 0.14

3.59 ± 0.30

ns

Urea nitrogen, mg/dL

28.13 ± 1.17

32.29 ± 1.90

30.88 ± 1.33

30.98 ± 2.42

ns

Creatinin, mg/dL

1.27 ± 0.04

1.29 ± 0.04

1.25 ± 0.04

1.10 ± 0.08

ns

AST, U/L

17.1 (15.2–18.3)

22.1 (18.3–30.9)

16.55 (14.6–19.00)

24.6 (21.55–28.1)

<0.001

ALT, U/L

15.3 (12.55–18.4)

28.9 (22.5–44.5)

15.6 (12.7–21.6)

41.75 (32.9–52.9)

<0.001

γ-GT, U/L

19.9 (16.26–23.79)

28.96 (24.3–36.1)

23.49 (19.79–36.74)

36.97 (27.79–72.65)

<0.001

ALP, U/L

224.5 (202–249)

231.5 (195–278)

243 (190–316)

228.5 (186.5–271)

ns

SBP, mmHg

127.65 ± 4.43

130.84 ± 4.49

136.79 ± 4.53

137.02 ± 4.40

ns

DBP, mmHg

78.15 ± 2.37

84.39 ± 3.76

79.95 ± 2.50

80.70 ± 2.10

ns

LS, kPa

2.33 ± 0.48

5.46 ± 0.37

4.77 ± 0.32

7.00 ± 0.51

<0.001

RBC, ×1012/L

4.66 ± 0.11

4.9 ± 0.09

4.96 ± 0.09

4.96 ± 0.13

ns

Platelet, ×109/L

221.05 ± 11.63

223.91 ± 10.65

224.64 ± 9.21

240.1 ± 8.27

ns

APRI, –

0.22 (0.15–0.25)

0.28 (0.19–0.41)

0.18 (0.15–0.21)

0.24 (0.22–0.30)

<0.05

WBC, ×109/L

5.5 (5.2–6.5)

5.5 (5.1–6.9)

6.6 (5.7–7.6)

6.65 (5.55–7.55)

ns

Hemoglobin, g/dl

14 (12–15)

14 (14–15)

14.5 (12–16)

14 (12–15.5)

ns

RDW, %

14 (14–15)

14 (14–14)

14.5 (14–15)

14 (14–15)

ns

MCV, fL

87 (86–89)

85 (83–88)

84.5 (82–88)

82 (79–89)

ns

  1. Continuous variables with normal and non-normal distribution were described as mean ± SEM and median (IQR), respectively
  2. NAFLD nonalcoholic fatty liver disease, T2DM type 2 diabetes mellitus, n number, WC waist circumference, WHR waist-to-hip ratio, BMI body mass index, FBG fasting blood glucose, HOMA-IR homeostasis model assessment of insulin resistance, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ALT alanine amino transferase, AST aspartate amino transferase, ɤ-GT gamma glutamyl transferase, ALP alkaline phosphatase, LS liver stiffness, SBP systolic blood pressure, DBP diastolic blood pressure, RBC red blood cell, WBC white blood cell, MCV mean corpuscular volume, RDW red cell distribution width, APRI aspartate amino transferase to platelet ratio index, ns non-significant
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us